WO1999027921A3 - Compositions and methods for modulating the activity of fibroblast growth factor - Google Patents

Compositions and methods for modulating the activity of fibroblast growth factor Download PDF

Info

Publication number
WO1999027921A3
WO1999027921A3 PCT/JP1998/005440 JP9805440W WO9927921A3 WO 1999027921 A3 WO1999027921 A3 WO 1999027921A3 JP 9805440 W JP9805440 W JP 9805440W WO 9927921 A3 WO9927921 A3 WO 9927921A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
activity
fgf
modulating
compositions
Prior art date
Application number
PCT/JP1998/005440
Other languages
French (fr)
Other versions
WO1999027921A2 (en
Inventor
Takatoshi Kawai
Ramnarayan Kalyanaraman
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Priority to AU13506/99A priority Critical patent/AU1350699A/en
Publication of WO1999027921A2 publication Critical patent/WO1999027921A2/en
Publication of WO1999027921A3 publication Critical patent/WO1999027921A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods for using bis-sulfonamide compounds of formula (I) and pharmaceutical compositions containing the compounds of formula (I) or pharmaceutically acceptable derivatives thereof for modulating the activity of the FGF family of peptides are provided. Methods for inhibiting the binding of an FGF peptide to an FGF receptor by contacting the receptor with a bis-sulfonamide compound of formula (I) are provided. Methods for treating FGF-mediated disorders by administering effective amounts of one or more of these bis-sulfonamides or prodrugs thereof that inhibit the activity of one or more FGF peptide are also provided.
PCT/JP1998/005440 1997-12-03 1998-12-02 Compositions and methods for modulating the activity of fibroblast growth factor WO1999027921A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13506/99A AU1350699A (en) 1997-12-03 1998-12-02 Compositions and methods for modulating the activity of fibroblast growth factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98446297A 1997-12-03 1997-12-03
US08/984,462 1997-12-03

Publications (2)

Publication Number Publication Date
WO1999027921A2 WO1999027921A2 (en) 1999-06-10
WO1999027921A3 true WO1999027921A3 (en) 1999-07-22

Family

ID=25530579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/005440 WO1999027921A2 (en) 1997-12-03 1998-12-02 Compositions and methods for modulating the activity of fibroblast growth factor

Country Status (2)

Country Link
AU (1) AU1350699A (en)
WO (1) WO1999027921A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1596099A (en) * 1998-11-23 2000-06-13 Eisai Co. Ltd. Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists
IL145210A (en) * 2000-12-06 2011-12-29 Aposense Ltd Use of pmbc in the preparation of an agent for the selective binding of cells, a method for the detection of apoptosis and a pharmaceutical composition for the treatment of a disease characterized by the presence of apoptosis in cells, tissues or cellular structures
IL147812A0 (en) * 2001-03-16 2002-08-14 N S T Neurosurvival Technologi Method for targeting chemical compounds to cells and pharmaceutical compositions used therein
WO2004110339A2 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013072A1 (en) * 1991-12-20 1993-07-08 Italfarmaco S.P.A. 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents
WO1998050342A1 (en) * 1997-05-08 1998-11-12 Smithkline Beecham Corporation Protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013072A1 (en) * 1991-12-20 1993-07-08 Italfarmaco S.P.A. 5-isoquinolinesulfonamide derivatives as protein kinase inhibiting agents
WO1998050342A1 (en) * 1997-05-08 1998-11-12 Smithkline Beecham Corporation Protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAWANISHI ET AL: "structure -activity relationships of diamines, dicarboxmides and disulfonamides on vinblastine accumulation in P388/ADR cells", CHEM PHARM BULL, vol. 42, no. 7, 1994, pages 149 - 1462, XP002103766 *

Also Published As

Publication number Publication date
WO1999027921A2 (en) 1999-06-10
AU1350699A (en) 1999-06-16

Similar Documents

Publication Publication Date Title
AU646230B2 (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
KR930003912A (en) Congestive Heart Failure Treatment Cure
MX9505182A (en) Therapeutical composition for topical application, containing a p substance antagonist.
IS4396A (en) inhalation Compounds
EP1586322A3 (en) Compositions for inhibition of anglogenesis
BG100635A (en) Substituted n-/indol-2-carbonyl/- - alanineamides and their derivatives as antidiabestic preparations
HK1001769A1 (en) Thienyl-, furyl-, pyrrolyl-and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
CA2102780A1 (en) Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU3153097A (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
HU9603592D0 (en) Aryl-sulfonamido-hydroxamic acids of matrix-metalloproteinase-inhibiting activity
WO2004052847A3 (en) Tricyclic steroid hormone nuclear receptor modulators
NZ515529A (en) Benzene derivatives, preparation method and pharmaceutical compositions containing same
WO1992019211A3 (en) Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
RU94045278A (en) Use of 2-phenyl-3-aroylbenzothiophenes for vasomotor symptom and associated psychological disorder inhibition associated with postclimacteric syndrome
EP1228072A4 (en) Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
CA2270177A1 (en) Transdermal administration of ment
WO1998009599A3 (en) The new use of dicaffeoylquinic acid for treating hepatitis b and the diseases related with retrovirus, and the new caffeoylquinic acid derivatives
WO1999029640A3 (en) Compositions and methods for modulating the activity of fibroblast growth factor
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
AU5090393A (en) Platelet aggregation inhibitors
ZA985142B (en) Captopril retard.
EP0412940A3 (en) Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure
NO985956L (en) Mixture for improved uptake of polar drugs from mucosal surfaces
WO1996023771A3 (en) Platelet aggregation inhibitors
WO1999027921A3 (en) Compositions and methods for modulating the activity of fibroblast growth factor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA